2185 — Shanghai Bio-heart Biological Technology Co Balance Sheet
0.000.00%
Last trade - 00:00- HK$1.01bn
- HK$1.13bn
- CNY44.93m
Annual balance sheet for Shanghai Bio-heart Biological Technology Co, fiscal year end - December 31st, CNY millions except per share, conversion factor applied.
2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | 2025 December 31st | |
|---|---|---|---|---|---|
| Period Length: | — | — | — | — | — |
| Source: | ARS | ARS | ARS | ARS | PRESS |
| Standards: | IFRS | IFRS | IFRS | IFRS | — |
| Status: | Final | Final | Final | Final | Final |
| Cash | |||||
| Cash and Equivalents | |||||
| Short Term Investments | |||||
| Cash and Short Term Investments | 709 | 451 | 369 | 202 | 249 |
| Net Total Accounts Receivable | |||||
| Net Total Receivables | 8.91 | 5.8 | 6.12 | 0 | 19.6 |
| Total Inventory | |||||
| Prepaid Expenses | |||||
| Total Other Current Assets | |||||
| Total Current Assets | 757 | 542 | 408 | 299 | 382 |
| Gross Property, Plant And Equipment | |||||
| Accumulated Depreciation | |||||
| Net Property, Plant And Equipment | 72.3 | 76 | 30.9 | 51.6 | 62.5 |
| Net Goodwill | |||||
| Net Intangible Assets | |||||
| Long Term Investments | |||||
| Long Term Notes Receivable | |||||
| Other Long Term Assets | |||||
| Total Assets | 1,115 | 982 | 818 | 734 | 832 |
| Accounts Payable | |||||
| Accrued Expenses | |||||
| Notes Payable / Short Term Debt | |||||
| Current Portion of Long Term Debt / Capital Leases | |||||
| Total Other Current Liabilities | |||||
| Total Current Liabilities | 36.8 | 28.8 | 20.1 | 19.6 | 25 |
| Long Term Debt | |||||
| Capital Lease Obligations | |||||
| Total Long Term Debt | |||||
| Total Debt | |||||
| Deferred Income Tax | |||||
| Minority Interest | |||||
| Total Other Liabilities | |||||
| Total Liabilities | 119 | 98.3 | 69.5 | 73.3 | 398 |
| Common Stock | |||||
| Additional Paid In Capital | |||||
| Retained Earnings (Accumulated Deficit) | |||||
| Treasury Stock | |||||
| Total Equity | 996 | 883 | 748 | 660 | 435 |
| Total Liabilities & Shareholders' Equity | 1,115 | 982 | 818 | 734 | 832 |
| Total Common Shares Outstanding |